TAKE16.78

TAKE Limited

· Pharma & Health
₹ CrorePeersVIMTALABSSUVENMcap ₹248 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×1.0150.772.462.11
Interest Burden (Pretax/EBIT) ×5.55-0.10-2.30-3.49
EBIT Margin %-32.54-3.55-2.05
Asset Turnover ×0.740.001.501.50
Financial Leverage (Assets/Equity) ×-9.931.781.171.17
ROE (5-step product) %1,339.7035.1126.59
ROE (reported, avg-equity basis) %1,348.13182.5335.0035.00
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.